The validation cohort differed significantly from the derivation cohort in terms of age, HF duration and symptoms, comorbidities (obesity—body mass index, dyslipidaemia, anaemia and chronic kidney disease), heart rate, NT-proBNP and their required loop diuretics dosage (Table S1, Appendix B). This evidence concerns the gene NPPB and chronic kidney disease.